Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JHL1101 vs Rituximab in CD20+ B-cell Lymphoma
NCT03670888Phase 1Terminated
- Sponsor
- Eden Biologics, Inc.
- Start
- Nov 2018
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rituximab biosimilar JHL1101 in B cell lymphoma (2 arms), sponsored by Eden Biologics, Inc. Primary endpoint: Area Under the Serum Concentration-Time Curve From Time Zero to Time t at 91 days. Started Nov 2018; status: terminated.
02
Drugs
rituximab biosimilar JHL1101
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT03670888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03670888.